Endo International has been granted a patent for a recombinant nucleic acid molecule encoding collagenase I and collagenase II, along with methods for preparation and use. The invention includes releasing collagenase prior to therapeutic administration. GlobalData’s report on Endo International gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Endo International Plc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Endo International, was a key innovation area identified from patents. Endo International's grant share as of February 2024 was 64%. Grant share is based on the ratio of number of grants to total number of patents.

Patent granted for recombinant nucleic acid encoding collagenase

Source: United States Patent and Trademark Office (USPTO). Credit: Endo International Plc

A recently granted patent (Publication Number: US11879141B2) discloses a recombinant nucleic acid molecule containing a polynucleotide that encodes the amino acid sequence of SEQ ID NO: 6, along with a heterologous regulatory sequence that is operably linked to the polynucleotide. This molecule can also be fused to a marker sequence, which may encode various polypeptides such as a glutathione-S-transferase (GST) fusion protein, a hemagglutinin A (HA) polypeptide from influenza, or a hexa-histidine peptide.

Furthermore, the patent claims a vector containing this recombinant nucleic acid molecule, with the vector specified to be a plasmid. It also includes a recombinant host cell comprising the vector, with the host cell being selected from various types including bacterial, fungal, insect, plant, and mammalian cells. The method outlined in the patent involves producing collagenase II by culturing the recombinant host cell under suitable conditions for expression of the polynucleotide and subsequently recovering the collagenase II. The host cell options for this method range from E. coli to mammalian cells like Chinese hamster ovary cells (CHO) or Lactococcus lactis.

To know more about GlobalData’s detailed insights on Endo International, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies